J. Brantley Thrasher, MD, professor of urology at the University of Kansas Medical Center, Kansas City, discusses key research in advanced prostate cancer.
“This year at the AUA annual meeting, we will get an update on apalutamide (Erleada) and its effect on outcomes and quality of life in non-metastatic castration-resistant prostate cancer.
Additionally, we will get a better understanding of which patients with lymph node involvement after radical prostatectomy benefit most from adjuvant XRT + androgen deprivation therapy and how accurately positron emission tomography scans in these patients identify true lymph node recurrence burden.
Finally, expect to hear more on the effects of statins in men on ADT for advanced prostate cancer.”
Dr. Thrasher’s abstract picks:
PD10-02: Adjuvant radiation with androgen deprivation therapy for men with lymph node metastases following radical prostatectomy: Identifying men who benefit
PD10-03: Assessing the under-estimation of nodal tumour burden by 68Ga-PSMA and 11c-choline PET/CT scan in patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer: A large multi-institutional analysis
PD10-11: Prostate-specific antigen (PSA) outcomes in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA): results from phase III SPARTAN study
Eric J. Small
PD14-03: Prediction of treatment resistance under abiraterone and enzalutmide via detection of AR-V7 in peripheral whole blood of castration-resistant prostate cancer patients
MP52-20: Patient reported outcomes (PROs) in SPARTAN, a phase 3, double-blind, randomized study of apalutamide (APA) plus androgen deprivation therapy (ADT) vs placebo plus ADT in men with nonmetastatic castration-resistant prostate cancer (nmCRPC)
Eric J. Small
MP87-07: Statin use is associated with improved prostate cancer-specific outcomes in white but not black men initiating androgen deprivation therapy
MP87-15: Use of statins in combination with androgen deprivation therapy in patients with advanced prostate cancer: impact on oncological outcomes.